Skip to main content
SpringerLink
Log in

Radiopharmaceuticals for SPET

  • Chapter
The Clinical Applications of SPET

Part of the book series: Developments in Nuclear Medicine ((DNUM,volume 25))

  • 38 Accesses

Abstract

A scintigram reflects the biodistribution of a radiopharmaceutical at a moment in time, or to be more precise, during the period of time which is required to accumulate the relevant data. The added value of a SPET study is that it provides a more precise geometric detail of the biodistribution of the radiopharmaceutical than planar imaging. In order to be able to take advantage of this it is desirable that the radiopharmaceutical should not be metabolised or transported in significant quantities during the data acquisition otherwise artifacts will ensue.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bull U von, et al. DSPECT.Förtschr Röntgenstr 1983;139:351–8.

    Article  CAS  Google Scholar 

  2. SubramanianG, McAfee JG, Blair RJ, et al. Technetium 99m methylene diphosphonate: Asuperior agent for Skeletal Imaging. J Nucl Med 1975;16:744–55.

    CAS  PubMed  Google Scholar 

  3. Cox PH. Thepharmacological behaviour of Technetium in bone, bone marrow and joints. In:Cox PH ed.Progress in Radiopharmacology. Amsterdam: Elsevier, 1979: 109–27.

    Google Scholar 

  4. Schrijver M de. Scintigraphy ofinflammation with nanometer sized colloidal tracers. Dordrecht: Kluwer AcademicPublishers 1989: 67–87.

    Chapter  Google Scholar 

  5. Mclntyre PA.In:Subramanian G, Rhodes BA, Cooper JF, et al.Radiopharmaceuticals New York: VJ Society of Nuclear Medicine, 1975: 343–8.

    Google Scholar 

  6. Davies MA. Ibid:267–81.

    Google Scholar 

  7. Pillay M, Shapiro B. Practical aspects of lung ventilation studies with Aerosols. Nucl GeneeskBull 1984:4; 159–64 [in Dutch].

    Google Scholar 

  8. Pillay M,Akkermans JA and Cox PH. A high efficiency ultrasound nebuliser forradioaerosol studies of the lungs. Eur J Nucl Med 1987:14;400–2.

    Google Scholar 

  9. Durovnic N,Pillay M and Cox PH. The stability of 99m Tc DTPA and 99mTc HIDA following ultrasound nebulisation. Eur J Nucl Med 1988:14;400–2.

    Google Scholar 

  10. Cox PH. Technetium complexes for Renal scintigraphy. In: Progress inRadiopharmacology. PH Cox, ed. The Hague: Martinus Nijhoff 1982: 31–44.

    Chapter  Google Scholar 

  11. Fazio F, et al. Tomographic assessment of regional cerebral perfusion usingintravenous I-123 HIPDM. J Comput Assist Tomogr 1984:8;911–21.

    Article  CAS  PubMed  Google Scholar 

  12. Ell PJ, et al. Cerebral blood flow studies with Iodine-123 labelled amines.Lancet,1983: 1348–52.

    Google Scholar 

  13. Holman BL, etal. Biodistributionanddosimetry of N-Isopropyl-p-diiodoamphetamine in the primate. J Nucl Med1983:24;922–31.

    CAS  PubMed  Google Scholar 

  14. Van Royen EA, etal.Cerebral blood flow imaging with Thallium 201 diethyldithiocarbamate. J NuclMed 1987:28; 178–83.

    PubMed  Google Scholar 

  15. Volkert WA, et al.99m Tc propylene amine oxime a potential brain radiopharmaceutical.Eur J Nucl Med 1984:9;511–6.

    Article  CAS  PubMed  Google Scholar 

  16. EuropeanPatent 0123504 B1, 1989.

    Google Scholar 

  17. Costa DC, etal.The in vivo distribution of 99m Tc HMPAO in normal man. Nucl Med Commun1986:7;647–58.

    CAS  PubMed  Google Scholar 

  18. SharpFF, et al.Technetium 99m HMPAO sterioisomers as potential agents for imaging regionalcerebral blood flow. J Nucl Med 1986:27; 171–7.

    CAS  PubMed  Google Scholar 

  19. Siccardi AG, etal.Technetium ECD a new brain imaging agent. J Nucl Med 1989:30;599–604.

    Google Scholar 

  20. LeveilleJ, etal.Characterisation of Technetium 99m ECD for brain perfusion imaging. J Nucl Med1989:30;902–1010.

    Google Scholar 

  21. GeorgeMS, etal.Neuroactivation and neuroimaging with SPET. London: Springer, 1991: 21.

    Chapter  Google Scholar 

  22. Bossuyt MS, etal.Tc99m MRF20 a new brain perfusion agent suitable for SPECT imaging. Eur J NuclMed 1990:16;418.

    Google Scholar 

  23. Verhoef NPLG, Pharmacological implications of neuroreceptor imaging. Eur J Nucl Med1991:18;482–502.

    Article  Google Scholar 

  24. Lebowitz E, etal.Thallium-201 for medical use. J Nucl Med 1975:16;151–55.

    CAS  PubMed  Google Scholar 

  25. Cox PH. Thecomparative radiopharmacology of Thallium-201 in relation to Potassium. In: PHCox ed. Progress in Radiopharmacology. Amsterdam: Elsevier North Holland 1981:19–28.

    Google Scholar 

  26. Mohiuaddin SM, etal. Comparison of adenosine and exercise Thallium-201 single photon emissioncomputed tomography myocardial perfusion imaging. J Am Coll Cardiol1992:19;248–57.

    Article  Google Scholar 

  27. Pennel DJ, et al.Dobutamine Thallium myocardium perfusion tomography. J Am Coll Cardiol1991:18;1471–9.

    Article  Google Scholar 

  28. Quinones MA, etal. Exercise echocardiography versus Tl-201 single photon emission computedtomography in evaluation of coronary artery disease analysis of 292 patients.Circulation 1992:85; 1026–31.

    Article  CAS  PubMed  Google Scholar 

  29. Holman BL, et al.A new Technetium-99m labelled myocardial imaging agenthexakis[t-butylisonitrile]. Initial experience in the Human. J Nucl Med1984:25; 1350–5.

    CAS  PubMed  Google Scholar 

  30. Wackers FJT, etal. Technetium-99m hexakis 2 methoxyisobutylisonitrile: human biodistribution,dosimetry, safety and preliminary comparison to Thallium-201 for myocardialperfusion. J Nucl Med 1989:30;301–11.

    CAS  PubMed  Google Scholar 

  31. Kahn JK, et al.Quantitative rotational tomography with Tl-201 and Tc-99m 2 methoxyisobutylnitrile. A direct comparison in normal individuals and in patients withcoronary artery disease. Circulation 1989:79; 1282–93.

    Article  CAS  PubMed  Google Scholar 

  32. Gibbons RJ, etal. Feasibility of tomographic 99m-Tc hexakis-2-methoxy-2-methylpropylisonitrile for the assessment of myocardial area at risk and theeffect of treatment in acute myocardial infarction. Circulation 1989:80;1277–86.

    Article  CAS  PubMed  Google Scholar 

  33. Santoro GM, et al. Singlephoton emission computed tomography with Technetium-99mHexakis-2-methoxyisobutylnitrile in acute myocardial infarction before andafter thrombolytic treatment: Assessment of salvaged myocardium and prediction oflate functional recovery. J Am Coll Cardiol 1990:15;301–14.

    Article  CAS  PubMed  Google Scholar 

  34. Narra RK, et al.A neutral Technetium-99m complex for myocardial imaging. J Nucl Med1989:30;1830–7.

    CAS  PubMed  Google Scholar 

  35. Fleming RM, etal. Comparison of Technetium-99m terboroxime tomography with automatedquantitative coronary arteriography and Thallium-201 tomographic imaging. J AmColl Cardiol 1991:17;1297–1302.

    Article  CAS  PubMed  Google Scholar 

  36. Henzlova MJ, andMachac J. Clinical utility of Technetium-99m terboroxime myocardial washoutimaging. J Nucl Med 1994:35;575–9.

    CAS  PubMed  Google Scholar 

  37. Higley B, et al.Technetium-99m 1,2 bis[bis(2-ethoxyethyl)phosphino]ethane: humanbiodistribution, dosimetry and safety of a new myocardial imaging agent. J NuclMed 1993:34;30–8.

    CAS  PubMed  Google Scholar 

  38. Jain D, et al.Biokinetics of Technetium-99m tetrofosmin: myocardial perfusion imaging agent:implications for a one day imaging protocol. J Nucl Med 1993:34;1254–9.

    CAS  PubMed  Google Scholar 

  39. Rigo P, et al.Technetium-99m tetrofosmin myocardial imaging: a comparison with Thallium-201and angiography. J Nucl Med 1994:35;587–93.

    CAS  PubMed  Google Scholar 

  40. Tamaki N, et al.Myocardial tomography using Technetium-99m tetrofosmin to evaluate coronaryartery disease. J Nucl Med 1994:35;594–600.

    CAS  PubMed  Google Scholar 

  41. Khaw BA, et al.Specificity of localisation of myosin specific antibody fragments inexperimental myocardial infarction. Circulation 1979:60;1527–31.

    Article  CAS  PubMed  Google Scholar 

  42. Idem. Myocardialdamage delineated by Indium-111 antimyosin Fab and Technetium-99mPyrophosphate. J Nucl Med 1987:28;76–82.

    Google Scholar 

  43. Bhattacharya S,Lahiri A. Antimyosin antibody imaging in myocardial infarction. In: Baum RP, et al ed. Clinicaluse of antibodies. Dordrecht: Kluwer Academic Publishers, 1991: 69–83.

    Google Scholar 

  44. Ell PJ, Khan O.The role of Technetium-99m Phosphates in the context of acute myocardialinfarction. In: PH Cox ed. Progress in Radiopharmacology 2. Amsterdam: ElsevierNorth Holland, 1981: 75–83.

    Google Scholar 

  45. Robinson JR, Lee AW. Radioiodinated fatty acids for heart imaging: iodine monochlorideaddition compared with iodine replacement labelling. J Nucl Med 1975:16;17–21.

    CAS  PubMed  Google Scholar 

  46. Machulla HJ, et al. Comparativeevaluation of fatty acids labelled C-11,Cl-34m, Br-77,I-123 for metabolicstudies of myocardium. J Nucl Med 1978:19;298–302.

    CAS  PubMed  Google Scholar 

  47. Machulla HJ, et al. Biochemicalconcepts and synthesis of radioiodinated phenylfatty acid for in vivo metabolicstudies of the myocardium. Eur J Nucl Med 1980:5; 171–3.

    Article  CAS  PubMed  Google Scholar 

  48. Angelberger P, et al. 1–123 and1–131 labelled p-Iodophenylpentadecanoic acid [p-IPPA]: simplified preparation.Biodistribution in mice, rabbits and patients. In: PH Cox ed. Progress inRadiopharmacology 2.Amsterdam: Elsevier North Holland, 1981: 61–74.

    Google Scholar 

  49. CorbettJ. Clinical experience with Iodine-123 Iodophenylpentadecanoic acid. J Nucl Med1994:[suppl]32S–7S.

    Google Scholar 

  50. Vyska K, et al. Regionalmyocardial free fatty acid extraction in normal and ischaemic myocardium.Circulation 1988:78;1218–33.

    Article  CAS  PubMed  Google Scholar 

  51. Hansen CL, et al.Iodine-123 phenylpentadecanoic acid and single photon emission computedtomography in identifying left ventricular regional metabolic abnormalities inpatients with coronary artery disease: comparison with Thallium-201 myocardialtomography. J Am Coll Cardiol 1988:12;78–87.

    Article  CAS  PubMed  Google Scholar 

  52. Hoeflin F.Routine 18F-2-deoxy-2-fluoro-d-glucose myocardial tomography using a normallarge field of view gamma camera. Angiology 1989:40; 1058–64.

    Article  Google Scholar 

  53. Idem. Detectionof non-perfused, viable myocardium with 18F FDG using a specially designedgamma camera. A simple method to detect hibernating myocardium. Acta RadiolSuppl 1991:376;133–4.

    Google Scholar 

  54. Perkins AC, PimmMV. Immunoscintigraphy practical aspects and clinical applications. New York:Wiley Lisse, 1991: 193 [General reference].

    Google Scholar 

  55. Baum RP, et alEditors. Clinical use of antibodies. Dordrecht: Kluwer Academic Publishers,1991: 81.

    Google Scholar 

  56. Goldenberg DM.New developments in monoclonal antibodies for cancer detection and therapy. C ACancer J Clin 1994:44;43–64.

    Article  CAS  Google Scholar 

  57. Bakker WH.Radiopharmaceuticals for scintigraphy of somatostatin receptor positivetumours. Rotterdam: PhD Thesis Erasmus University 1992.

    Google Scholar 

  58. Krenning EP, etal. Localisation of endocrine related tumours with radioiodinated analogue ofsomatostatin. Lancet 1989:l;242–4.

    Article  Google Scholar 

  59. Lamberts SWJ, etal. Somatostatin receptor imaging in the localisation of endocrine tumours. N Eng J Med 1990:323; 1246–49.

    Article  CAS  Google Scholar 

  60. Hoefnagel CA, etal. Radionuclide diagnosis and therapy of neural crest tumours using Iodine-131metaiodobenzylguanidine. J Nucl Med 1987:28;308–14.

    CAS  PubMed  Google Scholar 

  61. Hoefnagel CA, et al. Methodology and problems of single photon emission tomography using Iodine-131metaiodobenzylguanidine. Der Nuklearmediziner 1987: 4;317–23.

    Google Scholar 

  62. Hoefnagel CA, etal. Single photon emission tomography using meta-1311iodobenzylguanidine inmalignant pheochromocytoma and neuroblastoma: case reports. J Med Imaging1987:l;57–60.

    Google Scholar 

Download references

Authors
  1. P. H. Cox
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Nuclear Medicine, Dr. Daniel den Hoed Cancer Centre, P.O. Box 5201, 3008, AE Rotterdam, The Netherlands

    Peter H. Cox  & M. Pillay  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Cox, P.H. (1995). Radiopharmaceuticals for SPET. In: Cox, P.H., Pillay, M. (eds) The Clinical Applications of SPET. Developments in Nuclear Medicine, vol 25. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-0229-2_3

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-0229-2_3

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-4102-7

  • Online ISBN: 978-94-011-0229-2

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation